Golimumab for the Treatment of Refractory Behcet's Uveitis

Status Terminated

Clinical Trial Summary

The aim of this single-center prospective study is to evaluate the efficacy and safety of Golimumab （GOL）, fully humanized anti-tumor necrosis factor (TNF)-α monoclonal antibody, in the treatment of refractory Uveitis of Behçet's disease (BDU), to verify its effects on decreasing the dose of cortical steroids, and to determine whether it can reduce BDU recurrence.

Clinical Trial Description

Uveitis of Behçet's disease (BDU) is the most common form of ocular manifestations, which is also the leading cause of irreversible visual impairment. The aim of the study is to improve the treatment strategy of the disease as well as to reduce blindness. Monoclonal anti-TNF antibodies were recommended in 2018 recommendations for treating eye involvement affecting the posterior segment (level of evidence: IIA; strength of recommendation: B), Infliximab was mentioned for the treatment of initial or recurrent episode of acute sight-threatening uveitis. Golimumab （GOL）is a fully-humanized anti-TNF-α monoclonal antibody, retrospective study on non-infectious uveitis and BDU has obtained promising results. This single-center prospective study is to evaluate the efficacy and safety of GOL in the treatment of refractory BDU, to verify its effects on tapering the dose of corticosteroids, and to determine whether it can reduce BDU recurrence. We aim to enroll nine refractory BDU patients with acute onset posterior uveitis, with difficulty tapering corticosteroids while being treated with at least one of the commonly used immunosuppressants. All participants will receive GOL monthly for six months, oral immunosuppressants will remain unchanged. During follow-up, intraocular inflammation status, BCVA, as well as extraocular manifestations, will be recorded. The primary endpoints are the efficacy of the first dose of GOL, and the recurrence of uveitis after 12 months of treatment. Secondary endpoints other than intraocular inflammation will be achieved on each follow-up visit, as the quality of life improvements, side effects, recurrence of uveitis, and corticosteroids-tapering effects. On statistical analysis, the self-control treatment efficiency and recurrence rate difference will be determined using T-test of paired samples at a significance level of 0.05(2-sided). To ensure the interest of the participants, our study has been reviewed by the ethics committee, and drug clinical research liability insurance was prepared. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04218565
Study type	Interventional
Source	Peking Union Medical College Hospital
Contact
Status	Terminated
Phase	Phase 2
Start date	February 15, 2020
Completion date	December 15, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04101604` - Biomarkers of Common Eye Diseases
Active, not recruiting	`NCT04704609` - Imaging Quantification of Inflammation (IQI)
Completed	`NCT03173144` - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Withdrawn	`NCT01280669` - Intravitreal Sirolimus as Therapeutic Approach to Uveitis	Phase 2
Terminated	`NCT02907814` - Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography	N/A
Active, not recruiting	`NCT02252328` - Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients	Phase 2/Phase 3
Completed	`NCT04183387` - Simvastatin in Uveitis	Phase 2
Completed	`NCT01983488` - Clinical Outcome in Uveitis
Withdrawn	`NCT00499551` - A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis	Phase 1/Phase 2
Completed	`NCT00132691` - Multicenter Uveitis Steroid Treatment (MUST) Trial	Phase 4
Completed	`NCT00476593` - Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications	N/A
Terminated	`NCT00114062` - Study to Treat Uveitis Associated Macular Edema	Phase 2
Completed	`NCT00001867` - Effect of Pregnancy on Uveitis	N/A
Completed	`NCT00379275` - Eye and Immunogenetic Features of Sarcoidosis	N/A
Active, not recruiting	`NCT03828019` - Adalimumab vs. Conventional Immunosuppression for Uveitis Trial	Phase 3
Terminated	`NCT01939691` - Macular Edema Nepafenac vs. Difluprednate Uveitis Trial	Phase 4
Active, not recruiting	`NCT03889860` - Objective Choroidal Thickness Measurements in Uveitis
Completed	`NCT00070759` - Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis	Phase 2
Recruiting	`NCT05486468` - The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment	Phase 3
Active, not recruiting	`NCT05385757` - UNICORNS: Uveitis in Childhood Prospective National Cohort Study

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.